These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26855958)

  • 1. Trials are not for the benefit of patients.
    Kapitein P
    Ann Transl Med; 2016 Jan; 4(1):22. PubMed ID: 26855958
    [No Abstract]   [Full Text] [Related]  

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
    Miller FG; Joffe S
    Clin Trials; 2008; 5(6):617-23. PubMed ID: 19029210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage.
    Westhoff G; Cotter AM; Tolosa JE
    Cochrane Database Syst Rev; 2013 Oct; (10):CD001808. PubMed ID: 24173606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
    Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
    Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
    Tsujino K; Shiraishi J; Tsuji T; Kurata T; Kawaguchi T; Kubo A; Takada M
    Ann Oncol; 2010 Aug; 21(8):1668-1674. PubMed ID: 20064832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trials stopped early for benefit: a systematic review.
    Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
    JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid with or without vitamin B12 for cognition and dementia.
    Malouf M; Grimley EJ; Areosa SA
    Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
    Ohorodnyk P; Eisenhauer EA; Booth CM
    Eur J Cancer; 2009 Sep; 45(13):2249-52. PubMed ID: 19545996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit.
    Murad MH; Guyatt GH; Domecq JP; Vernooij RWM; Erwin PJ; Meerpohl JJ; Prutsky GJ; Akl EA; Mueller K; Bassler D; Schandelmaier S; Walter SD; Busse JW; Kasenda B; Pagano G; Pardo-Hernandez H; Montori VM; Wang Z; Briel M
    J Clin Epidemiol; 2017 Feb; 82():12-19. PubMed ID: 27832953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diet, lifestyle, and nonstatin trials: review of time to benefit.
    Denke MA
    Am J Cardiol; 2005 Sep; 96(5A):3F-10F. PubMed ID: 16126018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
    Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
    J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
    de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
    Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in time to benefit among clinical trials of cholesterol-lowering drugs.
    Barter PJ; Waters DD
    J Clin Lipidol; 2018; 12(4):857-862. PubMed ID: 29779997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
    Del Paggio JC; Azariah B; Sullivan R; Hopman WM; James FV; Roshni S; Tannock IF; Booth CM
    Ann Oncol; 2017 Jan; 28(1):157-162. PubMed ID: 27742650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personal benefit, or benefiting others? Deciding whether to take part in clinical trials.
    Locock L; Smith L
    Clin Trials; 2011 Feb; 8(1):85-93. PubMed ID: 21163854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carotid endarterectomy for symptomatic carotid stenosis.
    Rerkasem K; Rothwell PM
    Cochrane Database Syst Rev; 2011 Apr; (4):CD001081. PubMed ID: 21491381
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.